01 1Chongqing Carelife Pharmaceutical Co., Ltd.
01 1MITOXANTRONE HYDROCHLORIDE
01 1China
NDC Package Code : 58598-0005
Start Marketing Date : 2017-07-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
A Mitoxantrone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mitoxantrone, including repackagers and relabelers. The FDA regulates Mitoxantrone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mitoxantrone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mitoxantrone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mitoxantrone supplier is an individual or a company that provides Mitoxantrone active pharmaceutical ingredient (API) or Mitoxantrone finished formulations upon request. The Mitoxantrone suppliers may include Mitoxantrone API manufacturers, exporters, distributors and traders.
click here to find a list of Mitoxantrone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Mitoxantrone as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Mitoxantrone API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Mitoxantrone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Mitoxantrone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Mitoxantrone NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Mitoxantrone suppliers with NDC on PharmaCompass.
We have 1 companies offering Mitoxantrone
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
